Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid LeukemiaRIZZIERI, David A; O'BRIEN, Jenny A; MOORE, Joseph O et al.Cancer. 2009, Vol 115, Num 13, pp 2922-2929, issn 0008-543X, 8 p.Article

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B studyFARAG, Sherif S; RUPPERT, Amy S; STAMBERG, Judith et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 482-493, issn 0732-183X, 12 p.Article

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461BYRD, John C; RUPPERT, Amy S; MAYER, Robert J et al.Journal of clinical oncology. 2004, Vol 22, Num 6, pp 1087-1094, issn 0732-183X, 8 p.Article

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML, within the ELN Favorable genetic categoryMETZELER, Klaus H; BECKER, Heiko; POWELL, Bayard L et al.Blood. 2011, Vol 118, Num 26, pp 6920-6929, issn 0006-4971, 10 p.Article

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBECKER, Heiko; MARCUCCI, Guido; WU, Yue-Zhong et al.Blood. 2010, Vol 116, Num 5, pp 788-792, issn 0006-4971, 5 p.Article

Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia : evidence for antigen-driven intraclonal diversificationVOLKHEIMER, Alicia D; WEINBERG, J. Brice; BEASLEY, Bethany E et al.Blood. 2007, Vol 109, Num 4, pp 1559-1567, issn 0006-4971, 9 p.Article

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaWEINBERG, J. Brice; VOLKHEIMER, Alicia D; RIZZIERI, David A et al.American journal of hematology. 2007, Vol 82, Num 12, pp 1063-1070, issn 0361-8609, 8 p.Article

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621KOLITZ, Jonathan E; GEORGE, Stephen L; CALIGIURI, Michael A et al.Journal of clinical oncology. 2004, Vol 22, Num 21, pp 4290-4301, issn 0732-183X, 12 p.Article

Burkitt lymphoma arising in organ transplant recipients: A clinicopathologic study of five casesGONG, Jerald Z; STENZEL, Timothy T; BENNETT, Ellen R et al.The American journal of surgical pathology. 2003, Vol 27, Num 6, pp 818-827, issn 0147-5185, 10 p.Article

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBECKER, Heiko; MAHARRY, Kati; CARTER, Thomas H et al.Haematologica (Roma). 2011, Vol 96, Num 10, pp 1488-1495, issn 0390-6078, 8 p.Article

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetCHRISTENSEN, Dale J; CHEN, Youwei; GOCKERMAN, Jon P et al.Blood. 2011, Vol 118, Num 15, pp 4150-4158, issn 0006-4971, 9 p.Article

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySCHWIND, Sebastian; MARCUCCI, Guido; METZELER, Klaus H et al.Blood. 2010, Vol 116, Num 25, pp 5660-5669, issn 0006-4971, 10 p.Article

Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease : Cure balanced against complicationsKOONTZ, Bridget F; KIRKPATRICK, John P; CLOUGH, Robert W et al.Journal of clinical oncology. 2006, Vol 24, Num 4, pp 605-611, issn 0732-183X, 7 p.Article

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype : A cancer and leukemia group b studyMARCUCCI, Guido; BALDUS, Claudia D; BAER, Maria R et al.Journal of clinical oncology. 2005, Vol 23, Num 36, pp 9234-9242, issn 0732-183X, 9 p.Article

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaRIZZIERI, David A; SAND, Gregory J; FOSTER, Tracy et al.Cancer. 2004, Vol 100, Num 11, pp 2408-2414, issn 0008-543X, 7 p.Article

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaEISFELD, Ann-Kathrin; MARCUCCI, Guido; MENDLER, Jason H et al.Blood. 2012, Vol 120, Num 2, pp 249-258, issn 0006-4971, 10 p.Article

FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyWHITMAN, Susan P; MAHARRY, Kati; JING WEN et al.Blood. 2010, Vol 116, Num 18, pp 3622-3626, issn 0006-4971, 5 p.Article

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without OblimersenO'BRIEN, Susan; MOORE, Joseph O; RAI, Kanti R et al.Journal of clinical oncology. 2009, Vol 27, Num 31, pp 5208-5212, issn 0732-183X, 5 p.Article

Phase 1 trial study of ¹³¹I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaRIZZIERI, David A; AKABANI, Gamal; PEGRAM, Charles N et al.Blood. 2004, Vol 104, Num 3, pp 642-648, issn 0006-4971, 7 p.Article

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B studyBALDUS, Claudia D; TANNER, Stephan M; ALLEN, Steven L et al.Blood. 2003, Vol 102, Num 5, pp 1613-1618, issn 0006-4971, 6 p.Article

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461FARAG, Sherif S; ARCHER, Kellie J; LARSON, Richard A et al.International journal of oncology. 2002, Vol 21, Num 5, pp 1041-1051, issn 1019-6439Article

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)BYRD, John C; MROZEK, Krzysztof; KODURU, Prasad R. K et al.Blood. 2002, Vol 100, Num 13, pp 4325-4336, issn 0006-4971, 12 p.Article

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid LeukemiaMROZEK, Krzysztof; MARCUCCI, Guido; PETTENATI, Mark J et al.Journal of clinical oncology. 2012, Vol 30, Num 36, pp 4515-4523, issn 0732-183X, 9 p.Article

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyMETZELER, Klaus H; MAHARRY, Kati; WU, Yue-Zhong et al.Journal of clinical oncology. 2011, Vol 29, Num 10, pp 1373-1381, issn 0732-183X, 9 p.Article

Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone: Results of a Multicenter Phase III StudyCORTES, Jorge; MOORE, Joseph O; ABBOUD, Camille N et al.Journal of clinical oncology. 2010, Vol 28, Num 27, pp 4207-4213, issn 0732-183X, 7 p.Article